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Hungering for New Mechanism-Based Strategies to Break the Obesity-Cancer Link: 1	
A Narrative Review 2	
 3	
Research Snapshot 4	
Research Question: What are the mechanisms through which obesity increases cancer 5	
risk and progression? Does implementation of dietary or lifestyle interventions attenuate 6	
obesity-associated cancer risk factors?  7	
 8	
Key Findings: A traditional literature review revealed that obesity-associated metabolic 9	
perturbations are emerging as major drivers of obesity-related cancer including 10	
alterations in growth factor signaling, inflammation and angiogenesis. Preclinical 11	
evidence suggests that dietary interventions such as calorie restriction, intermittent 12	
fasting, ketogenic diet and physical activity have the potential to reverse some of these 13	
obesity-associated alterations; however, more clinical data is needed to confirm 14	
translation to human subjects. 15	
 16	
Abstract  17	
The prevalence of obesity, an established risk factor for many cancers, has increased 18	
dramatically over the past 50 years in the United States and many other countries. 19	
Relative to normoweight cancer patients, obese cancer patients often have poorer 20	
prognoses, resistance to chemotherapies, and are more likely to develop distant 21	
metastases. Recent progress on elucidating the mechanisms underlying the obesity-cancer 22	
connection suggests that obesity exerts pleomorphic effects on pathways related to tumor 23	
	 2
development and progression, and thus there are multiple opportunities for prevention 24	
and treatment of obesity-related cancers.  We now know that obesity can impact each of 25	
the well-established hallmarks of cancer, but obesity-associated perturbations in systemic 26	
metabolism and inflammation, and the interactions of these perturbations with cancer cell 27	
energetics, are emerging as the primary drivers of obesity-associated cancer development 28	
and progression. Several obesity-related host factors, including components of the 29	
adipose secretome and structural components of the tumor microenvironment, are 30	
extrinsic to, and interact with, the intrinsic molecular characteristics of cancer cells 31	
(including cancer stem cells). Each will be considered in the context of potential 32	
preventive and therapeutic strategies to reduce the burden of obesity-related cancers.  33	
This review will focus on current knowledge of the mechanisms behind the obesity-34	
cancer link as well as relevant dietary and lifestyle interventions that are being 35	
implemented in preclinical and clinical trials, with the ultimate goal of reducing 36	
incidence and progression of obesity-related cancers. 37	
 38	
Abbreviations : AMP kinase (AMPK); body mass index (BMI); brown adipose tissue 39	
(BAT); calorie restriction (CR); cardiovascular disease (CVD); estrogen receptor (ER); 40	
free fatty acids (FFA); insulin-like growth factor-1 (IGF-1); interleukin (IL); intermittent 41	
fasting (IF); ketogenic diet (KD); monocyte chemo-attractant protein-1 (MCP-1); 42	
mammalian target of rapamycin (mTOR); non-alcoholic steatohepatitis (NASH); nuclear 43	
factor kappa-light-chain-enhancer of B cells (NFκB); plasminogen activator inhibitor-1 44	
(PAI-1); phospatidylinositol-3 kinase (PI3K); peroxisome proliferator-activated receptor 45	
(PPAR); physical activity (PA); signal transducer and activator of transcription (STAT); 46	
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tumor necrosis factor-α (TNF-α); type II Diabetes (T2DM); vascular endothelial growth 47	
factor (VEGF); white adipose tissue (WAT) 48	
  49	
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Introduction  50	
Over the past half century in the United States the prevalence of obesity, defined as body 51	
mass index (BMI) of 30 kg/m2 or greater, has tripled.  Today nearly 40% of adults and 52	
20% of children in the United States are obese1. Worldwide, more than 600 million adults 53	
are obese and 2.1 billion are overweight2. Obesity increases risk of several chronic 54	
diseases and comorbidities including type II diabetes (T2DM), cardiovascular disease 55	
(CVD), hypertension, chronic inflammation and, as discussed in this review, many types 56	
of cancer3. 57	
 58	
As illustrated in Figure 1, and based on the recent report from the International Agency 59	
for Research on Cancer, risk of 13 distinct cancer types is increased with excess body 60	
fatness4.  These obesity-associated cancers include breast (in postmenopausal women), 61	
ovarian, liver, gallbladder, kidney, colon, pancreatic, gastric, esophageal, endometrial, 62	
thyroid, multiple myeloma, and meningioma4.  Overall, an estimated 13% of incident 63	
cases worldwide, and approximately 20% of incident cases in Europe and North America, 64	
are attributable to obesity5. Aside from higher risk of developing cancer, obese 65	
individuals are more likely to have reduced response to anticancer therapies6, and obesity 66	
is implicated in approximately 20% of all cancer-related mortalities7.  This includes 67	
prostate cancer, for which obesity increases progression but not incidence8. Here, we 68	
discuss (with a focus on developing mechanism-based intervention strategies) many ways 69	
in which obesity can influence normal epithelial tissue homeostasis and cancer 70	
development and/or progression, including metabolic perturbations involving hormonal, 71	
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growth factor and inflammatory alterations, as well as interactions with the 72	
microenvironment.  73	
 74	
Methods 75	
A traditional literature review was performed to describe the multiple mechanisms 76	
underlying the obesity-cancer link, as well as dietary interventions targeting those 77	
mechanisms for cancer prevention and treatment. Searches were completed using 78	
PubMed and Google Scholar. A variety of key words were searched including obesity, 79	
metabolic syndrome, cancer prevention, cancer treatment, calorie restriction, intermittent 80	
fasting, ketogenic diet, and physical activity.  81	
 82	
Obesity Impacts Each Hallmark of Cancer 83	
Hanahan and Weinberg identified essential biological capabilities acquired by all cancer 84	
cells during the multistep development of tumors in their classic article titled “The 85	
Hallmarks of Cancer” first published in 20009 and updated in their 2011 “Hallmarks of 86	
Cancer: the Next Generation”10.  These essential aberrations of cancer cells, include 87	
sustaining proliferative signaling, increased chronic inflammation, evading growth 88	
suppressors, resisting cell death, displaying genome instability, enabling replicative 89	
immortality, inducing angiogenesis, and activating processes related to invasion and 90	
metastasis. Conceptual progress in the decade between these two articles led to 91	
identification of additional hallmarks, including reprogramming of energy metabolism, 92	
evading immune destruction, and creation of the tumor microenvironment through 93	
recruitment of various non-cancerous cells.  Emerging evidence supports the concept that 94	
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metabolic reprogramming, inflammation, and genome instability (including epigenetic 95	
changes) represent the “hallmarks of hallmarks” and underlie many of the other essential 96	
aberrations of cancer.  In the case of cancer-associated metabolic reprogramming, cancer 97	
cells often preferentially metabolize glucose through glycolysis rather than oxidative 98	
phosphorylation (even under normoxic conditions) to generate substrate for cell 99	
division10-12.  Thus, citric acid cycle intermediates not utilized for ATP production are 100	
shuttled out of the mitochondria providing precursors for nucleotide, amino acid and lipid 101	
synthesis pathways for the dividing cell12. In this way, cancer cells readily take up and 102	
metabolize glucose to provide substrate for daughter cell production, with glucose 103	
transporters and glycolytic enzymes being elevated in most cancers13.  104	
 105	
Metabolic Syndrome and Systemic Metabolic Perturbations 106	
Interactions between cellular energetics in cancer cells and systemic metabolic changes 107	
associated with obesity are emerging as critical drivers of obesity-related cancer. 108	
Intrinsically linked with obesity and associated with alterations in several cancer-related 109	
host factors is metabolic syndrome, characterized by insulin resistance, hyperglycemia, 110	
hypertension and dyslipidemia. In both obesity and metabolic syndrome, alterations occur 111	
in circulating levels of insulin and insulin-like growth factor (IGF)-1; adipokines (e.g. 112	
leptin, adiponectin, resistin, and monocyte chemotactic protein (MCP)-1); inflammatory 113	
factors (e.g. interleukins (IL)-6, 10, and 17, interferon- and tumor necrosis factor (TNF)-114	
); several chemokines; lipid mediators such as prostaglandin E2; and vascular-115	
associated factors (e.g. vascular endothelial growth factor (VEGF) and plasminogen 116	
activator inhibitor (PAI)-1)14-16.  Each of these factors has a putative role in development 117	
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and progression of cancer, as well as a number of other chronic diseases14,16 including 118	
CVD and T2DM, and will be explored in more detail below.  119	
 120	
Insulin, IGF-1 and Growth Factor Signaling 121	
In response to elevated blood glucose level, pancreatic β-cells release insulin, a peptide 122	
hormone that stimulates peripheral uptake of glucose, glucose metabolism, and energy 123	
storage pathways. As depicted in Figure 2, obesity and metabolic syndrome are 124	
characterized by hyperglycemia and associated aberrations in insulin signaling, growth 125	
factor signaling, and glucose metabolism17. One growth factor implicated in cancer risk 126	
and progression is IGF-1. Produced primarily following growth hormone stimulation in 127	
the liver, IGF-1 functions as a regulator of growth and development processes18. IGF 128	
binding proteins bind to IGF-1 in circulation and limit its bioavailability to bind to IGF-1 129	
receptor and induce downstream signaling to promote growth and/or survival19. 130	
Hyperglycemia and hyperinsulinemia, hallmarks of metabolic syndrome, increase IGF-1 131	
production and bioavailability. Hyperglycemia suppresses IGF-1 binding protein 132	
synthesis and hyperinsulinemia promotes expression of growth hormone receptor and 133	
subsequent IGF-1 synthesis17. Growth and survival functions of IGF-1 give it the 134	
potential to impact many hallmarks of cancer, including suppression of apoptosis and 135	
promotion of cell cycle progression, angiogenesis and metastatic potential20. As a result, 136	
elevated IGF-1 is established as a risk factor for many types of cancer19.  137	
 138	
IGF-1 receptor and insulin receptor stimulate the same downstream activation of 139	
phosphoinositide 3-kinase (PI3K)/Akt pathway (Figure 2), a pathway frequently altered 140	
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in epithelial cancers21. In response to these growth factors and nutrient availability, 141	
PI3K/Akt produces lipid messengers that initiate the Akt signaling cascade21, activating 142	
downstream mammalian target of rapamycin (mTOR) 22. When activated mTOR initiates 143	
downstream signaling that promotes cell growth, proliferation and survival. In response 144	
to low nutrient conditions AMP-activated kinase (AMPK), another energy responsive 145	
pathway, inhibits mTOR activation and downstream signaling23. Oncogenic signals or 146	
loss of tumor suppressors can activate mTOR and contribute to the hallmarks of cancer, 147	
promoting proliferation, survival, angiogenesis, and metastasis24. In preclinical models, 148	
blocking mTOR signaling with drugs such as rapamycin (mTOR inhibitor)25-27 and 149	
metformin (AMPK activator)25,28,29, block tumor-enhancing effects associated with the 150	
obese phenotype30. Interestingly, rapamycin has exhibited anti-inflammatory attributes, 151	
attenuating inflammation as well as tumor promotion, suggesting crosstalk between 152	
mTOR-related growth and survival signals and inflammatory signals31. 153	
 154	
Chronic Inflammation:  The Role of Adipose Tissue 155	
Mammals, including humans, have 2 major fat depots: subcutaneous and visceral (intra-156	
abdominal).  These adipose depots contain white adipose tissue (WAT) that stores energy 157	
in the form of triacylglycerol and brown adipose tissue (BAT) that dissipates energy by 158	
burning fatty acids to generate heat. WAT and BAT have important differences in their 159	
morphology, metabolism and transcriptional profiles.  White adipocytes have few 160	
mitochondria, low oxidative rate, and contain a unilocular lipid droplet comprised 161	
primarily of triacylglycerol, while brown adipocytes have a high number of mitochondria 162	
(hence the darker appearance), high rate of fatty acid and glucose uptake and oxidation, 163	
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and possess multilocular lipid droplets32. Moreover, the secretome of white versus brown 164	
adipocytes differs markedly (Figure 3); the former is characterized by secretion of leptin, 165	
resistin, PAI-1, inflammatory cytokines, and free fatty acids (FFA), while the latter is 166	
characterized by secretion of bone morphogenetic proteins, lactate (which induces 167	
uncoupling proteins), retinaldehyde, triiodothyonine (T3) and other factors associated 168	
with response to cold stress and/or increased energy expenditure32. Brown adipocytes 169	
also produce adiponectin (but not leptin) and fibroblast growth factor-21, which can be 170	
anti-inflammatory and insulin sensitizing32. WAT also contains a number of stromal cells 171	
including pre-adipocytes, vascular cells, fibroblasts and a host of immune cells such as 172	
adipose tissue macrophages33.  Increased WAT mass in obesity drives chronic 173	
inflammation in at least 3 ways, depicted in Figure 4 and summarized below:   174	
 175	
1.  Altered Adipose Secretome 176	
Leptin is an energy-sensing peptide hormone produced by adipocytes. Leptin levels, 177	
positively correlated with adiposity, function as an energy sensor through signaling to the 178	
hypothalamus, decreasing hunger cues, food intake and weight gain. Leptin release from 179	
adipocytes is stimulated by a variety of factors including insulin, TNFα, glucocorticoids, 180	
and estrogen34. In obesity, leptin is overproduced by adipocytes, reducing hypothalamic 181	
sensitivity to the signal35. Circulating leptin binds to various receptors in central nervous 182	
system and peripheral tissues, regulating processes including energy homeostasis, 183	
cytokine production, immune function, and carcinogenesis34,36. The leptin receptor OB-R, 184	
classified as a class I cytokine receptor, gives leptin the ability to activate signal 185	
transducer and activator of transcription (STAT) family transcription factors, resulting in 186	
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initiation of STAT-induced transcription programs for proliferation, cell growth and 187	
survival, migration and differentiation37. Deregulation of STATs activity is often 188	
observed in cancer38. 189	
 190	
Adiponectin, another peptide hormone secreted from adipocytes, functions as an energy 191	
sensor that promotes hunger and energy intake, opposing the functions of leptin. 192	
Although the most abundant hormone secreted from the WAT, adiponectin levels are 193	
negatively correlated with adiposity and release is stimulated during energy deficit. 194	
Adiponectin opposes obesity-associated metabolic alterations through regulating glucose 195	
metabolism, increasing insulin sensitivity and fatty acid oxidation, and reducing IGF-1 196	
signaling through activation of AMPK, inhibitor of downstream mTOR39. Adiponectin 197	
also attenuates inflammation through inhibition of nuclear factor kappa-light-chain-198	
enhancer of B cells (NF-B), which reduces expression of proinflammatory cytokines 199	
while increasing expression of anti-inflammatory cytokines40. Due to the anticancer 200	
functions of adiponectin, adiponectin agonists are emerging as possible chemotherapeutic 201	
agents, particularly for obesity-related cancers41. While associations between each of 202	
these adipokines and cancer risk are established, the leptin to adiponectin ratio is 203	
increasingly considered a more sensitive measure in evaluating cancer risk42. 204	
 205	
Sex hormones, including estrogen, androgens and progestogens, regulate a variety of 206	
growth and developmental processes including weight homeostasis43. Long established is 207	
the association between sex hormone levels and obesity44. In postmenopausal women, 208	
BMI is positively correlated with estrone, estradiol, and free estradiol45. Elevation of 209	
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estrogens is also detected in obese men44,46; however, testosterone levels are significantly 210	
reduced47. Alteration of sex hormones can result in several biological disorders including 211	
hypertension, menstrual disturbances, erectile dysfunction, gynecomastia, hirsutism, and 212	
increased adiposity44. Moreover, sex hormones have been implicated in risk and/or 213	
progression of multiple cancer types48. In prostate cancer, sex hormone levels are 214	
associated with disease progression, not disease risk49. Low levels of circulating 215	
testosterone correlates with aggressive disease progression50. Elevated estrogen levels are 216	
associated with increased risk of breast44,45,51, ovarian52, and endometrial cancers53.  217	
 218	
Menopausal status can also modulate sex hormone secretion and signaling in women. 219	
Prior to menopause, ovaries are the main site of estrogen production, whereas after 220	
menopause, peripheral sites including adipose tissue, are the main source of estrogen 221	
production. In postmenopausal, obese women adipose tissue serves as the main site of 222	
estrogen synthesis45. Once released, circulating estrogens bind to one of two estrogen 223	
receptors (ER), ERα or ERβ. Once bound, receptors dimerize and translocate to the 224	
nucleus where they bind to DNA or other transcription factors, influencing gene 225	
expression profiles that regulate growth, proliferation and differentiation54. In the context 226	
of cancer, the two receptors have differing roles. ERα is mitogenic and an established 227	
target in treatment of estrogen receptor-positive breast cancer, while ERβ is suggested to 228	
be tumor suppressive55. Obesity and postmenopausal status increases risk of ER-positive 229	
breast cancers compared with ER-negative breast cancer56. Due to the positive 230	
association between obesity, circulating estrogen and risk of ER-positive breast cancer, 231	
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aromatase inhibitors and ER antagonist, including tamoxifen, have been investigated for 232	
their effectiveness as adjuvant therapy57.  233	
 234	
2. Crown-Like Structures  235	
Obesity drives subclinical inflammation in visceral and subcutaneous WAT, 236	
characterized by crown-like structures, or rings of activated macrophages surrounding 237	
engorged or necrotic adipocytes (Figure 4).  This adipocyte-macrophage interaction 238	
results in a proinflammatory secretome from both cell types, activating the cellular 239	
transcription factor NF-kB, increasing levels of cytokines and other inflammatory factors, 240	
and triggering inflammation58. 241	
 242	
3. Adipose Remodeling and Lipid Infiltration in Other Tissues 243	
During conditions of low nutrient availability or increased energy needs, glucagon 244	
secretion stimulates lipolysis of adipocytes, releasing FFA into the blood stream59. 245	
Circulating FFA can then be utilized by peripheral tissues, providing substrate for β-246	
oxidation and serving as intermediates for energy production through the citric acid cycle 247	
and oxidative phosphorylation. Overnutrition remodels existing adipose tissue, expanding 248	
adipocyte number and size, and altering adipokine secretion, FFA flux, and adipocyte 249	
death60. In response, adipose stromal cells modify their functions to promote clearance of 250	
necrotic adipocytes and generation of new adipocytes and vasculature. Tissue remodeling 251	
in chronic overnutrition or obesity, results in sustained, low-grade inflammation and 252	
metabolic alterations60. As stated above, cancer cells adapt to changing energy needs for 253	
proliferation through metabolic reprogramming, increasing anaerobic metabolism  and 254	
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shunting citric acid cycle intermediates to synthetic pathways10,12. Production of daughter 255	
cells demands increased levels of FFA for formation of lipid bilayers, thus excess WAT 256	
promotes proliferation of tumor cells through provision of circulating FFA61. 257	
 258	
Chronic overnutrition can lead to lipid accumulation beyond capacity of adipose depots, 259	
leading to deposition of lipids in peripheral tissues including muscle, liver and pancreatic 260	
tissue62. Ectopic lipid intermediates exert lipotoxic effects, impairing cellular organelle 261	
functions, releasing inflammatory cytokines, and fostering development of insulin 262	
resistance63. Consequently, individuals can develop muscle dysfunction and hepatic and 263	
pancreatic steatosis, all of which have been positively correlated with insulin resistance 264	
and impaired lipid metabolism62.  265	
 266	
Nonalcoholic fatty liver disease, diagnosed as >5-10% liver fat content by weight in the 267	
absence of alcohol use or other liver disease, encompasses a variety of liver diseases 268	
including simple steatosis, nonalcoholic steatohepatitis (NASH) and cirrhosis64. One of 269	
the most common chronic diseases65-67, Nonalcoholic fatty liver disease is present in 65-270	
85% of obese patients64,68 with rapidly rising incidence among adults and children66,69. 271	
Excess accumulation of lipids in the liver, exerts lipotoxic effects including production of 272	
reactive oxygen species, activation of pro-inflammatory programs, and endoplasmic 273	
reticular stress, impairing function of cellular organelles and potentially inducing hepatic 274	
cell death70. Additionally, accumulation of lipids and pro-inflammatory cytokines 275	
promotes activation of intracellular kinases, leading to impaired insulin signaling and 276	
development of insulin resistance71. While simple steatosis is benign, NASH is more 277	
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detrimental, characterized by liver injury, inflammation and/or fibrosis. NASH can 278	
further result in the development of cirrhosis, liver failure, and hepatocellular 279	
carcinoma72.  280	
 281	
Deposition of adipocytes in the pancreas appears to occur early in obesity-associated 282	
pancreatic dysfunction, altering secretion and signaling of endocrine factors including 283	
insulin. Infiltrating fat in the pancreas has been associated with increased visceral WAT 284	
mass and insulin resistance73,74. These endocrine alterations further complicate the 285	
complex metabolic and inflammatory perturbations characterized in obesity and 286	
metabolic syndrome and can trigger the development of pancreatic steatosis, pancreatitis 287	
and/or nonalcoholic fatty pancreatic disease, established risk factors for pancreatic 288	
cancer73,74.  289	
 290	
Angiogenesis 291	
As adipose tissue depots expand in obesity, the existing vasculature must expand to meet 292	
demand. This outgrowth of new blood vessels is termed angiogenesis. Key mediators of 293	
this process include VEGF and PAI-1.  VEGF, is a potent angiogenic factor that is 294	
produced by adipocytes and tumor cells. VEGF acts on endothelial cells stimulating 295	
mitogenic and vascular permeability-enhancing activities75. Obesity is associated with 296	
increased circulating VEGF, and elevated VEGF correlates with poor prognosis for many 297	
obesity-related cancers76. PAI-1 is another angiogenic factor, produced by adipocytes, 298	
endothelial cells, and stromal cells in visceral WAT77, that is frequently elevated in obese 299	
subjects. Increased circulating PAI-1 is associated with increased risk of other chronic 300	
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diseases including CVD, T2DM and a number of cancers77. While interaction of 301	
angiogenic factors with proximal endothelial cells induce formation of local blood 302	
vessels, providing a route for oxygen and nutrient delivery and waste removal, these 303	
factors can also interact with peripheral tissues, facilitating angiogenesis, and potentially 304	
promoting progression at tumor sites. These newly formed blood vessels would 305	
potentially provide primary tumor mass with oxygen and nutrients to sustain proliferation 306	
and survival as well as a route for metastasis to distant sites. PAI-1 functionally inhibits 307	
plasminogen activators, thus regulating extracellular matrix integrity78. Extracellular 308	
matrix remodeling is a key feature of invasive disease, and integral in the development of 309	
metastatic lesions79. Due to the antitumorigenic potential of factors that modulate 310	
angiogenesis, targeted drugs have been developed. However, caution should be advised 311	
in administration of anti-angiogenic treatments in obese patients, as these drugs can 312	
induce hypoxia in primary tumors, potentially encouraging metastasis, already a concern 313	
in the obese population79. Elevation of these factors may also impact efficacy of 314	
treatment regimens, as excess circulating VEGF in obese patients contributes to reduced 315	
efficacy of anti-VEGF therapies (e.g. bevacizumab) compared with non-obese ovarian 316	
cancer patients80. 317	
 318	
Dietary Interventions Targeting Obesity for Cancer Prevention and Treatment 319	
Given the multifaceted role of obesity in promoting a protumorigenic microenvironment 320	
that facilitates tumor development and progression, interventions are urgently needed to 321	
break the obesity-cancer link.  To date, the only weight loss intervention in obese people 322	
consistently associated with reduced cancer risk is bariatric surgery81.  In light of the 323	
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expense and complications inherent in surgical weight loss approaches, current efforts are 324	
focusing on reducing adiposity through lifestyle and dietary interventions. To achieve 325	
reductions in weight and adiposity these interventions have aimed to 1) promote negative 326	
energy balance through either reduced energy intake via calorie restriction (CR) or 327	
intermittent fasting (IF) or through increased energy expenditure via physical activity 328	
(PA) or 2) implementation of ketogenic diet (KD) a dietary pattern associated with 329	
weight loss and reduced cancer progression. Preclinical and some clinical studies suggest 330	
that these interventions can favorably and inversely modulate cancer risk biomarkers 331	
including insulin, IGF-1, leptin, adiponectin, cytokines, angiogenic factors, and crown-332	
like structures compared to the obese state. Modulation of these biomarkers could result 333	
in downstream reductions in growth factor signaling, inflammation, and angiogenesis, 334	
attenuating cancer risk and progression (Figure 5).  335	
 336	
1. Calorie Restriction 337	
Calorie restriction (CR), defined as reduction of dietary energy intake without 338	
malnutrition, is broadly effective dietary intervention that significantly decreases 339	
adiposity. Preclinical models demonstrate 30% CR, compared with ad libitum-fed 340	
control, ameliorates risk factors and delays onset of cancer through metabolic alterations 341	
fostering increased insulin sensitivity and decreased serum glucose, growth factor 342	
signaling, inflammation, oxidative stress and angiogenesis82-85. These metabolic changes 343	
translate into significantly decreased cancer incidence in murine models86.  Due to long 344	
latency of cancer in humans, the literature does not have data linking CR directly with 345	
cancer incidence in humans. However, randomized control trials implementing long-term 346	
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20% CR in overweight human subjects has confirmed reduced adiposity, improved 347	
glucose homeostasis, increased adiponectin, and reduced leptin and inflammatory 348	
markers TNF and C-reactive protein87,88.  Substantial weight loss of >10% may be 349	
necessary to consistently gain these benefits89-91. 350	
 351	
Limited clinical studies exist on CR during cancer treatment. Direct application of CR in 352	
cancer patients is complicated by high rates of weight loss associated with cancer 353	
cachexia, a condition in which tumor-derived signals degrade muscle and adipose tissue. 354	
Emerging findings from preliminary clinical trials suggest that application of CR as an 355	
adjuvant therapy in combination with chemotherapy and/or radiation has potential to 356	
increase responsiveness to treatment92,93. 357	
 358	
2. Intermittent Fasting  359	
Preclinical and clinical studies have begun to explore implementation of intermittent 360	
fasting (IF), which may be easier for most people to adopt and may have beneficial 361	
metabolic effects relative to chronic CR. Human trials most often study one of three IF 362	
regimens: alternate day fasting, alternate day energy restriction (~75%) or 2 consecutive 363	
days of 65% energy restriction, the latter often referred to as intermittent calorie 364	
restriction94. Periods of IF stimulate reduced insulin and increased glucagon, resulting in 365	
increased lipolysis and fatty acid oxidation to provide alternate substrates for energy 366	
production. These metabolic alterations are accompanied by reductions in several cancer-367	
related risk factors including lower insulin resistance, inflammation, and circulating IGF-368	
195. The impact of IF on angiogenesis in the context of cancer remains unexplored in 369	
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currently published research. Preclinical studies with IF consistently exhibit a cancer 370	
preventative effect with reduced rates of tumor growth for multiple cancer types95-97. To 371	
our knowledge there is no published data on IF and cancer incidence in human subjects, 372	
although there are reports of favorable effects of IF in overweight human, including 373	
improved adipokine ratios and reduced inflammation96,98, suggesting the reported 374	
preclinical anticancer effects of IF may be translatable to humans.  375	
 376	
One IF regimen being examined as a breast cancer prevention strategy is called the 5:2 377	
diet and involves 5 days/week of a healthy diet, such as the Mediterranean diet, with two 378	
consecutive days of a low calorie, low carbohydrate diet.  The Mediterranean diet is 379	
primarily a plant-based diet high in fruits, vegetables, whole grains, legumes and nuts. 380	
Compared to North American dietary patterns, the Mediterranean diet has been 381	
associated with better control of body weight, reduction of cancer risk biomarkers and 382	
decreased cancer incidence99-103. The diet results in favorable modulation of 383	
inflammation, oxidative stress, and growth factor signaling. Combining a Mediterranean 384	
diet with 2 days of a very low calorie, low carbohydrate diet for one month in 24 obese 385	
women at high risk for breast cancer induced changes in breast tissue gene expression 386	
and metabolites associated with reduced risk of breast cancer104. 387	
 388	
Regarding the effects of IF on cancer prognosis, a study by Safdie, et al suggests IF 389	
during cancer therapy may decrease adverse effects of chemotherapy. Ten cancer patients 390	
(various cancer types) voluntarily fasted prior to (48-140 hours) or following (5-56 hours) 391	
chemotherapy treatment. Compared with non-restricted control subjects, fasting reduced 392	
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chemotherapy-induced side effects including fatigue, weakness and gastrointestinal side 393	
effects while exhibiting the same chemotherapy-induced reduction in tumor volume or 394	
biomarkers105. Following this ground breaking study, others have implemented IF in 395	
small scale clinical trials including de Groot, S., et al., 2015, where short term IF among 396	
stage II/III breast cancer patients was well tolerated, reduced signs of hematological 397	
toxicity and stimulated faster recovery from DNA damage in normal host peripheral 398	
blood mononuclear cells106. Limited preclinical findings suggest that IF may selectively 399	
protect healthy cells and make cancer cells more vulnerable to chemotherapeutic agents, 400	
reducing side-effects and increasing drug efficacy95. More research is needed to confirm 401	
these findings and identify underlying mechanisms. 402	
 403	
 404	
3. Physical Activity 405	
Engaging in physical activity (PA), alone or in combination with reduced dietary energy 406	
intake, can be another effective method in generating a negative energy balance, reducing 407	
weight and adiposity.  A published systematic review of the literature on PA in cancer 408	
survivors revealed that PA produced favorable modulation of insulin/IGF-1 pathways and 409	
inflammation107. Limited evidence from preclinical studies suggest that PA may also 410	
reduce the level of intratumoral mTOR activation, VEGF expression and 411	
angiogenesis108,109. Intervention studies suggest that reduction in these risk biomarkers 412	
associated with PA may be reliant on significant weight loss110-112. Furthermore, the 413	
amount of exercise can influence effectiveness of PA. For example, in one study PA did 414	
not significantly reduce inflammatory markers unless participants achieved 120 minutes 415	
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per week, just  short of the American Cancer Society’s recommendation of 150 416	
minutes113. Epidemiological and cohort studies confirm an anticancer potential and 417	
demonstrate a 20-30% reduction in cancer risk with substantial PA for multiple cancer 418	
types including breast, colon and endometrial114.  419	
 420	
PA is also safe and beneficial during cancer therapy for multiple cancer types115-117. Not 421	
only can PA improve body composition, it can also reduce unwanted side effects of 422	
treatment and improve physical functioning and quality of life parameters. A randomized 423	
control trial in stage II breast cancer patients found that 10 weeks of interval-based, 424	
aerobic exercise reduced chemotherapy-induced nausea and increased individual 425	
functional capacity118,119. Courneya, et al. findings suggest that PA may increase 426	
chemotherapy completion rate without causing adverse events such as lymphedema in 427	
breast cancer patients120.  Benefits are further exhibited in elderly patients with exercise 428	
during treatment improving memory and self-reported health and reducing fatigue121. 429	
Studies on exercise during treatment suggest that higher-intensity exercise provides more 430	
benefit than low-intensity exercise122.  431	
 432	
Despite the observed positive benefits of PA, important questions remain regarding 433	
intensity and amount of physical activity that must be performed to fully reap the 434	
benefits. Based on current knowledge, the American Cancer Society advises 150 minutes 435	
of moderate or 75 minutes of vigorous per week for cancer prevention and 436	
survivorship123. 437	
 438	
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4. Ketogenic Diet 439	
Ketogenic diet (KD) is a very-low carbohydrate diet with high fat and moderate protein 440	
composition. Low carbohydrate consumption reduces available glucose, a cancer cell’s 441	
preferred energy source, and increases catabolism of proteins and fats to provide 442	
gluconeogenic glucose and ketones. With prolonged consumption of KD, glycogen stores 443	
reach critical levels and the body is no longer able to oxidize fats to glucose via 444	
gluconeogenesis. This results in a shift to increased ketone production and physiological 445	
ketosis. Ketosis is not to be confused with ketoacidosis that is seen with diabetes mellitus. 446	
In ketosis there is less accumulation of ketones, as they are being used efficiently by the 447	
brain and body as an energy source, and individuals do not experience adverse side 448	
effects associated with ketoacidosis124.  Ketosis from KD favorably modulates many 449	
cancer risk biomarkers including IGF-1, leptin, adiponectin, inflammatory markers, and 450	
angiogenic factors (Figure 5)125-128. Preclinical studies suggest that KD can attenuate 451	
these markers without a reduction in caloric intake; however, weight loss may be 452	
needed129,130. KD may induce weight loss via several interrelated mechanisms, including: 453	
reduced appetite due to high protein intake, which can induce higher satiety, and high 454	
ketones, known to modulate appetite-regulating hormones; reduced caloric intake due to 455	
the satiety; reduced lipogenesis and increased lipolysis; greater metabolic efficiency; and 456	
increased metabolic cost of gluconeogenesis and ketogenesis124. 457	
 458	
Beneficial effects of the ketogenic diet have long been established for epilepsy and 459	
T2DM; emerging is its role in cancer prevention and treatment124. Early preclinical 460	
studies found KD reduced tumor burden and cachexia in a mouse model of colon 461	
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cancer131. Further preclinical models have confirmed these findings and extended benefits 462	
of decreased tumor growth and increased survival to other cancer types including 463	
malignant glioma, gastric and prostate cancers132. To date results from clinical trials 464	
focused on implementation of KD in cancer prevention and treatment have been limited, 465	
and ongoing clinical trials are addressing this gap in the literature with multiple cancer 466	
types133. 467	
 468	
It is important to also consider potential adverse effects of KD. Reduction of 469	
carbohydrate in KD is replaced with increased protein and fat. High protein intake has 470	
been linked to kidney damage134, although this is not widely accepted with other 471	
preclinical, human, and meta-analysis studies finding no evidence of renal damage with 472	
high protein intake124. Additionally, select preclinical studies have found long-term KD 473	
to cause dyslipidemia, hepatic steatosis and glucose intolerance135. More research is 474	
needed to evaluate the safety and efficacy of ketogenic diets as cancer prevention and 475	
treatment interventions.   476	
 477	
Summary and Conclusions 478	
A strong link between obesity and cancer risk has been established in the epidemiological 479	
and preclinical literature. Obesity is associated with several systemic metabolic 480	
perturbations that are correlated with increased cancer risk and/or poor prognosis, 481	
including dysregulation of insulin and growth factor signaling, adipokine signaling, 482	
inflammation, and angiogenesis. Establishment of this obesity-cancer link has spurred 483	
research focused on a variety of lifestyle and dietary interventions to promote a negative 484	
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energy balance, attain weight loss, attenuate risk biomarkers, and prevent obesity-485	
associated cancers. Preclinical and early clinical work on these putative anticancer dietary 486	
and lifestyle interventions, including CR, PA, IF, and KD, are also being evaluated, some 487	
showing promise in reducing cancer risk. Additionally, the literature suggests that these 488	
interventions may improve response to chemotherapy for multiple cancer types.  While 489	
many clinical studies have evaluated the safety and efficacy of PA as adjuvant therapy 490	
and suggest it is safe for patients, there are few clinical trials that evaluate the utilization 491	
of dietary interventions such as CR, IF, and KD as adjuvant therapy (Table 1). Future 492	
studies will need to focus on the safety and added benefit to current therapies, and should 493	
also consider the potential of the dietary interventions to sensitize patients and facilitate 494	
the use of lower doses of chemotherapy or radiation therapy to improve therapeutic 495	
response.  496	
 497	
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Figure Legends 867	
Figure 1: Obesity is associated with increased risk of developing and dying from the 868	
following cancers: breast (in postmenopausal women), ovarian, liver, gallbladder, kidney 869	
(renal cell), colon, pancreatic, gastric, esophageal (adenocarcinoma), endometrial, 870	
thyroid, multiple myeloma, and meningioma4.  In addition, obesity is associated with 871	
progression (but not incidence) of prostate cancer8. 872	
 873	
Figure 2: Obesity and metabolic syndrome result in many metabolic disturbances 874	
including elevations in circulating insulin, adipokines (e.g. leptin-to-adiponectin ratio), 875	
cytokines, angiogenic factors (PAI-1 and VEGF), as well as increased prevalence of 876	
adipose tissue crown-like structures, a marker of adipose inflammation. These factors can 877	
activate receptor tyrosine kinase signaling through the PI3 kinase (PI3K)/Akt/mammalian 878	
target of rapamycin (mTOR) pathway. An increase in steady state signaling through this 879	
pathway can drive increases in cellular proliferation and protein translation, and reinforce 880	
cancer-associated metabolic reprogramming. Activation of NF-B by proinflammatory 881	
cytokines, induces translocation to the nucleus and upregulates expression of genes 882	
involved in survival proliferation, inflammation and immune regulation. Together, 883	
obesity-associated elevation of growth factor signaling and inflammation and reduction 884	
of vascular integrity fosters a microenvironment favorable for tumorigenesis, increasing 885	
cancer risk and progression. 886	
 887	
Figure 3: The human body contains two types of adipocytes: white adipocytes (which 888	
have a unilocular lipid droplet) and brown adipocytes (which have many small lipid 889	
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droplets). When engorged with triglyceride, white adipocytes secrete a number of factors 890	
that promote growth factor signaling and inflammation including leptin, resistin, insulin-891	
like growth factor (IGF)-1, free fatty acids, tumor necrosis factor (TNF)-  and 892	
interleukin (IL)-6.  Additionally, they reduce production of anti-inflammatory 893	
adiponectin.  Brown adipocytes secrete several factors involved in thermogenesis, 894	
decreased inflammation, normalized insulin sensitivity and/or increased energy 895	
expenditure such as adiponectin, bone morphogenetic proteins, neuregulin-4, lactate, 896	
triiodothyronine (T3), retinaldehyde, and fibroblast growth factor (FGF)-21.   897	
 898	
Figure 4: In obesity, as adipocytes accumulate triglycerides, their secretomes shift 899	
towards the production of pro-inflammatory and/or insulin resistant molecules, including 900	
numerous cytokines, adipokines (e.g. leptin and resistin), and free fatty acids.  901	
Engorged/necrotic adipocytes attract macrophages and other immune cells that further 902	
contribute to the pro-inflammatory environment. The altered secretome resulting from 903	
macrophage-adipocyte interactions modulates several enzymes associated with increased 904	
inflammation-related lipid mediators (such as prostaglandins and leukotrienes) and 905	
hormones (such as aromatase, which converts androgens to estrogens). 906	
 907	
Figure 5: Dietary and lifestyle interventions of caloric restriction (CR), intermittent 908	
fasting (IF), physical activity (PA) and adherence to a ketogenic diet (KD), have been 909	
shown to reduce adiposity and favorably modulate many of the same cancer risk 910	
biomarkers that are impacted by obesity including: insulin, IGF-1, leptin, adiponectin, 911	
cytokines, angiogenic factors, and crown-like structures. These metabolic alterations 912	
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could result in downstream reductions in growth factor signaling, inflammation, and 913	
angiogenesis and attenuate cancer risk and progression. Metabolic alterations with CR, IF 914	
and PA interventions have been associated with reduced cancer risk and progression. 915	
While KD has not been linked to cancer risk, it has been demonstrated that adherence to 916	
KD reduces cancer risk and progression in preclinical studies. a) Insufficient evidence 917	
exist to conclude the impact of PA and IF on PAI-1 and VEGF expression. b) Current 918	
literature does not exist examining the impact of KD on crown-like structures. 919	
